Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Invasive Pneumococcal Disease

Sex eligibility

All sexes

Study type

Observational

Primary location

Kaiser Permanente Vaccine Study Center

Oakland, California, 94612, United States

About this study

No sampling as no subjects are enrolled

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Documented invasive pneumococcal disease (IPD), defined as recovery of an isolate of S pneumoniae from a normally sterile site in a member of the surveillance population.

Exclusion criteria

None

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

Incidence of IPD in the NCKP healthcare system in children 6 weeks through 5 years of age (prior to the sixth birthday) during each of the 5 years following introduction of Prevnar 13.

Time frame: 5 years

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Collaborators

Kaiser Permanente

Registry information

Official study title

A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus Pneumoniae After Introduction Into Routine Pediatric Use

Important dates

Study start: 2010
Primary completion: 2015
Study completion: 2015
First posted: May 21, 2010
Registry last updated: Dec 4, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed